Cadrenal Therapeutics (NASDAQ:CVKD) Trading Up 14.3% – Should You Buy?

Cadrenal Therapeutics, Inc. (NASDAQ:CVKD)’s stock price traded up 14.3% during trading on Wednesday . The company traded as high as $20.63 and last traded at $19.89. 125,227 shares were traded during mid-day trading, an increase of 114% from the average session volume of 58,609 shares. The stock had previously closed at $17.40.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright upped their price objective on shares of Cadrenal Therapeutics from $3.00 to $32.00 and gave the stock a “buy” rating in a research note on Monday, November 11th.

Cadrenal Therapeutics Trading Down 2.3 %

The firm has a market cap of $34.43 million, a PE ratio of -2.90 and a beta of 1.26. The stock’s 50-day simple moving average is $14.98.

Cadrenal Therapeutics (NASDAQ:CVKD) last issued its quarterly earnings results on Thursday, November 7th. The company reported ($2.18) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.83) by ($0.35). As a group, equities research analysts forecast that Cadrenal Therapeutics, Inc. will post -7.59 earnings per share for the current year.

Cadrenal Therapeutics Company Profile

Cadrenal Therapeutics, Inc operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome.